Onco Actu du 1er avril 2020

	4.12 BIOPSIES LIQUIDES
Grail Multi-Cancer Test Meets Validation Goals; Patients to Receive Results Under New Pilot [Genome Web] "We aren’t trying necessarily to find every neoplasm that exists. A test that does that would have an overdiagnosis problem," he explained. "You want to find the cancer that needs to be found, so that is the upside, maybe, of a sensitivity that is compelling … but not perfect."
New blood test study uses artificial intelligence to identify cancer. But it’s not ready for patients yet. [Cancer Research UK] More research is needed to improve the test’s ability to catch early cancers and we still need to explore how it might work in a real cancer screening scenario.
	5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
Drug Combination Could Boost the Effectiveness of Immunotherapy against Pancreatic Cancer [Memorial Sloan-Kettering Cancer Center] The two drugs, trametinib (Mekinist®) and palbociclib (Ibrance®), do not by themselves kill tumor cells. Instead, they trigger a state called senescence.
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
With latest FDA submission, Bristol Myers keeps pace with Celgene milestones [Biopharma Dive] With liso-cel’s application also securing a speedy review and Zeposia already approved, Bristol Myers now has a good chance to beat all of the deadlines tied to its $9-per-share payout to Celgene shareholders.
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA [bluebird bio] BLA submission includes results from pivotal Phase 2 KarMMa study evaluating ide-cel in a heavily pre-treated patient population with relapsed and refractory multiple myeloma.
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T [EndPoints] A new CAR-T therapy may be coming. And maybe $9 per share for Celgene investors, too.
Could CAR-T Version 2.0 Be on the Horizon? [Children's Hospital Los Angeles] Their study, recently published in the journal Leukemia, shows that these new CAR-T cells could be the answer to resistant leukemia. The new CAR-T cells targeting CD-19, CD-20 and CD-22 are significantly more effective than T-cells that target CD-19 alone.
	5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
Motion denied: Gilead still on the hook for $1.5B in damages over CAR-T patent dispute with Bristol Myers Squibb [EndPoints] Gilead’s bid to overturn a jury verdict that ordered it to pay Bristol Myers Squibb about $752 million for CAR-T patents owned by its subsidiary Juno Therapeutics has ended in vain.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
EMA Recommends Granting a Marketing Authorisation for Isatuximab [ESMO] It is intended for the treatment of multiple myeloma.
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
MD Anderson implements proactive measures due to 2019 novel coronavirus disease (COVID-19) [MD Anderson Cancer Center] “Our cancer patients are uniquely vulnerable to coronavirus. For this reason, we are committing to increased workforce precautions,” said Peter WT Pisters, M.D., president of MD Anderson.
NICE publishes second set of rapid COVID-19 guidelines [NICE] The new guidelines cover the provision of radiotherapy services and bone marrow transplant during the COVID-19 pandemic.
COVID-19 Infection and Related Challenges in Aviano Cancer Centre in Italy [ESMO] The latest situation, described in the article published in the Annals of Oncology, features tents built in front of each hospital entrance. These tents serve as triage areas.